Linked Life Data

11391089

Source:http://linkedlifedata.com/resource/pubmed/id/11391089

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2001-6-13
pubmed:abstractText
The emergence of cognition-enhancing drugs in the treatment of Alzheimer disease raises questions about quality of lives for those with dementia and for their caregivers, and about the perceptions of health care professionals. This pilot study analyzes a limited data from a series of three focus groups on the experience of treatment. These groups engaged both Alzheimer disease-affected persons, their caregivers, and a multidisciplinary professional core. We conclude that therapeutic goals need to be better addressed with patients and families, as well as better monitored, with the possibility of withdrawing therapy as appropriate. We also detected, as hypothesized, considerable disparity between the perspectives of professionals and consumers regarding the benefits of therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0893-0341
pubmed:author
pubmed:issnType
Print
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
80-8
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:articleTitle
A focus group on cognition-enhancing medications in Alzheimer disease: disparities between professionals and consumers.
pubmed:affiliation
Center for Biomedical Ethics, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106-4976, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't